Spyre Therapeutics Inc (NASDAQ: SYRE) kicked off on Friday, up 1.06% from the previous trading day, before settling in for the closing price of $22.68. Over the past 52 weeks, SYRE has traded in a range of $20.07-$47.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -37.38% over the last five years. While this was happening, its average annual earnings per share was recorded 91.31%. With a float of $48.60 million, this company’s outstanding shares have now reached $51.40 million.
The firm has a total of 30 workers. Let’s measure their productivity. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.
Spyre Therapeutics Inc (SYRE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc is 14.93%, while institutional ownership is 94.95%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 56.12% during the next five years compared to 23.71% growth over the previous five years of trading.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Take a look at Spyre Therapeutics Inc’s (SYRE) current performance indicators. Last quarter, stock had a quick ratio of 7.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.21, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.86 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Analysing the last 5-days average volume posted by the [Spyre Therapeutics Inc, SYRE], we can find that recorded value of 0.63 million was better than the volume posted last year of 0.59 million. As of the previous 9 days, the stock’s Stochastic %D was 49.37%. Additionally, its Average True Range was 1.40.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 13.34%, which indicates a significant decrease from 58.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.81% in the past 14 days, which was lower than the 59.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.45, while its 200-day Moving Average is $28.57. Now, the first resistance to watch is $23.26. This is followed by the second major resistance level at $23.61. The third major resistance level sits at $24.02. If the price goes on to break the first support level at $22.50, it is likely to go to the next support level at $22.09. Should the price break the second support level, the third support level stands at $21.74.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 51,431K Shares Outstanding. Its annual sales at the moment are 890 K in contrast with the sum of -338,790 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -69,030 K.
